Sanofi patents not obvious, rules Fed Circuit in Sandoz clash

10-11-2017

The US Court of Appeals for the Federal Circuit has affirmed a lower court’s ruling that two Sanofi-owned patents are not invalid as obvious.


Sanofi, Watson, US Court of Appeals for the Federal Circuit, patent, generics, Multaq, Sandoz,

LSIPR